http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
개별검색 DB통합검색이 안되는 DB는 DB아이콘을 클릭하여 이용하실 수 있습니다.
통계정보 및 조사
예술 / 패션
<해외전자자료 이용권한 안내>
- 이용 대상 : RISS의 모든 해외전자자료는 교수, 강사, 대학(원)생, 연구원, 대학직원에 한하여(로그인 필수) 이용 가능
- 구독대학 소속 이용자: RISS 해외전자자료 통합검색 및 등록된 대학IP 대역 내에서 24시간 무료 이용
- 미구독대학 소속 이용자: RISS 해외전자자료 통합검색을 통한 오후 4시~익일 오전 9시 무료 이용
※ 단, EBSCO ASC/BSC(오후 5시~익일 오전 9시 무료 이용)
Yong-Kyu,Chung,Shin,Hwang,Gi-Won,Song,Young-Joo,Lee,Ki-Hun,Kim,Chul-Soo,Ahn,Deok-Bog,Moon,Tae-Yong,Ha,Dong-Hwan,Jung,Gil-Chun,Park,Baek-Yeol,Ryoo,Sung-Gyu,Lee 한국간담췌외과학회 2018 Annals of hepato-biliary-pancreatic surgery Vol.22 No.4
Backgrounds/Aims: Hepatocellular carcinoma (HCC) recurrence following hepatic resection (HR) and liver transplantation (LT) remains a great concern. We assessed the antitumor effects of metformin in patients treated with sorafenib for HCC recurrence after HR or LT. Methods: The two clinical retrospective studies involved metformin therapy of 304 HR patients and 74 LT recipients who were treated with sorafenib. Results: In the study involving patients who had undergone HR, death occurred in 245 of the 304 patients (80.6%) during a median follow-up of 10.2 months after sorafenib administration. The metformin HR group (group 1; n=40) showed no prognostic difference in progression-free and overall survival rates compared with the all-HR control group (group 3; n=241) and propensity score-matched HR control group (group 4; n=80). In the clinical study of recipients exposed to LT, death occurred in 62 of the 74 patients (83.8%) during a median follow-up of 13.6 months (range: 3-76 months) after sorafenib administration. The metformin LT group (group 5; n=14) showed no prognostic difference in progression-free and overall survival rates compared with the all-LT control group (group 7; n=43) and propensity score-matched LT control group (group 8; n=28). Conclusions: Our clinical studies demonstrated absence of synergistic antitumor effects of metformin. Further high-volume studies are necessary to assess the role of metformin in patients treated with sorafenib for advanced HCC.
Gil-Chun,Park,Shin,Hwang,Chul-Soo,Ahn,Ki-Hun,Kim,Deok-Bog,Moon,Tae,Yong,Ha,Gi,Won,Song,Dong-Hwan,Jung,Young-In,Yoon,Hui-Dong,Cho,Jae-Hyun,Kwon,Yong-Kyu,Chung,Sang-Hyun,Kang,Jin-Uk,Choi,I-Ji,Jung,Sung 대한의학회 2020 Journal of Korean medical science Vol.35 No.11
Background: Hepatocellular carcinoma (HCC) recurrence and development of de novo malignancy (DNM) after liver transplantation (LT) are the major causes of late recipient death. Methods: We analyzed the incidence of extrahepatic DNM following living donor LT according to the status of pretransplant hepatic malignancy. We selected 2,076 adult patients who underwent primary LDLT during 7 years from January 2010 to December 2016. Results: The pretransplant hepatic malignancy group (n = 1,012) showed 45 cases (4.4%) of the following extrahepatic DNMs: posttransplant lymphoproliferative disease (PTLD) in 10; lung cancer in 10; stomach cancer in 6; colorectal cancer in 5; urinary bladder cancer in 3; and other cancers in 11. The pretransplant no hepatic malignancy group (n = 1,064) showed 25 cases (2.3%) of the following extrahepatic DNMs: colorectal cancer in 3; stomach cancer in 3; leukemia in 3; lung cancer in 3; PTLD in 2; prostate cancer in 2; and other cancers in 9. Incidences of extrahepatic DNM in the pretransplant hepatic malignancy and no hepatic malignancy groups were as follows: 1.1% and 0.5% at 1 year, 3.2% and 2.0% at 3 years, 4.6% and 2.5% at 5 years, and 5.4% and 2.8% at 8 years, respectively (P = 0.006). Their overall patient survival rates were as follows: 97.3% and 97.2% at 1 year, 91.6% and 95.9% at 3 years, 89.8% and 95.4% at 5 years, and 89.2% and 95.4% at 8 years, respectively (P < 0.001). Pretransplant hepatic malignancy was the only significant risk factor for posttransplant extrahepatic DNM. Conclusion: Our results suggest that patients who had pretransplant hepatic malignancy be followed up more strictly because they have a potential risk of primary hepatic malignancy recurrence as well as a higher risk of extrahepatic DNM than patients without pretransplant hepatic malignancy.
The efficiency enhancement of organic light-emitting diodes with an oxygen-plasma-treated substrateand an electron-injection layer of alkali-metal carbonates (Li2CO3 and Cs2CO3) was studied. The Li2CO3 and the Cs2CO3 carbonates were thermally evaporated to a thickness of 1 nm. Forthe device with a Li2CO3 layer, the luminance at 9.25 V of the device with the plasma-treated ITOsubstrate was found to be improved by approximately 10% compared to that of the device with theplasma-untreated ITO substrate, and the maximum luminance driving voltage was lowered by 1.0V. For the device with a Cs2CO3 layer, the luminance at 11.25 V of the device with the oxygenplasma-treated ITO substrate was found to be improved by approximately 42.3% compared to thatof the device with plasma-untreated ITO substrate, and the maximum luminance driving voltagewas lowered by 1.25 V. Especially, the luminous efficiencies of the devices with the Li2CO3 and theCs2CO3 layers were confirmed to have been increased by 50.0% and 78.1%, respectively, when theoxygen-plasma-treated ITO substrate was used.
( Yong-kyu Chung ), ( Shin Hwang ), ( Chul-soo Ahn ), ( Ki-hun Kim ), ( Deok-bog Moon ), ( Tae-yong Ha ), ( Gi-won Song ), ( Dong-hwan Jung ), ( Gil-chun Park ), ( Young-in Yoon ), ( Woo-hyoung Kang ), ( Hwui-do) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: When splitting a liver for adult and pediatric graft recipients, the retained left medial section (S4) will undergo ischemic necrosis and the right trisection graft becomes an extended right liver (ERL) graft. We investigated the fates of the retained S4 and its prognostic impact in adult split liver transplantation (SLT) using an ERL graft. Methods: This was a retrospective analysis of 25 adult SLT recipients who received split ERL grafts. Results: The mean model for end-stage liver disease (MELD) score was 27.3±10.9 and graft-recipient weight ratio (GRWR) was 1.98±0.44. The mean donor age was 26.5±7.7 years. The split ERL graft weight was 1181.5±252.8 g, which resulted in a mean GRWR of 1.98±0.44. Computed tomography of the retained S4 parenchyma revealed small ischemic necrosis in 16 (64.0%) patients and large ischemic necrosis in the remaining 9 (36.0%) patients. No S4-associated biliary complications were developed. The peak liver enzyme levels were higher in the large S4 ischemic necrosis group (P≤0.002). The mean GRWR was 1.87±0.43 in the 9 patients with large ischemic necrosis and 2.10±0.44 in the 15 cases with small ischemic necrosis (P=0.28). The retained S4 parenchyma showed gradual atrophy on follow-up imaging studies. The amount of S4 ischemic necrosis was not associated with graft (P=0.59) or patient (P=0.24) survival. A MELD score >30 and pretransplant ventilator support were associated with inferior outcomes. Conclusions: The amount of S4 ischemic necrosis is not a prognostic factor in adult SLT recipients, probably due to a sufficiently large GRWR.
Networked Control System (NCS) has evolved in the past decade through the advances in communication technology. The problems involved in NCS are broadly classified into two categories namely network issues due to network and control performance due to system network. The network problems are related to bandwidth allocation, scheduling and network security, and the control problems deal with stability analysis and delay compensation. Various delays with variable length occur due to sharing a common network medium. Though most delays are very less and mostly neglected, the network induced delay is significant. It occurs when sensors, actuators, and controllers exchange data packet across the communication network. Networked induced delay arises from sensor to controller and controller to actuator. This paper presents an adaptive delay compensation process for efficient control. Though Smith predictor has been commonly used as dead time compensators, it is not adaptive to match with the stochastic behavior of network characteristics. Time delay adaptive compensation gives an effective control to solve dead time, and creates a virtual environment using the plant model and computed delay which is used to compensate the effect of delay. This approach is simulated using TrueTime simulator that is a Matlab Simulink based simulator facilitates co-simulation of controller task execution in real-time kernels, network transmissions and continuous plant dynamics for NCS. The simulation result is analyzed, and it is confirmed that this control provides good performance.
Gil,Yong,Lee,Suk,Jin,Ha,Jong,Hyun,Jung,Dong,Ho,Seo,Jong,Yul,Park,Su,Rin,Kim,Nam,Woo,Park,Dong,Keon,Kweon,Sang,Hoo,Park,Cheon,Seok,Park 한국응용생명화학회(구 한국농화학회) 2009 Applied Biological Chemistry (Appl Biol Chem) Vol.52 No.3